Current SCD Studies (1):
• GBT 440-041 - An Open-label, Expanded Access Protocol to provide early access to treatment with Voxelotor prior to market authorization for pediatric patients age 6 months to < 4 years with sickle cell disease who have no alternative treatment options. • GBT 131 - Phase 3, Randomized study assessing whether inclacumab infusion can prevent vaso-occlusive crisis in participants ≥ 12 years with Sickle cell disease. • GBT 132 - A Phase 3 Randomized study evaluating whether a single inclacumab infusion given just prior to, during, or around the time of discharge can reduce readmission due to VOCs in participants ≥ 12years with Sickle Cell Disease.
Made with FlippingBook Digital Proposal Creator